ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $24.92, but opened at $24.12. ArriVent BioPharma shares last traded at $23.97, with a volume of 4,184 shares.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a "buy" rating and set a $36.00 price target on shares of ArriVent BioPharma in a research report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $36.80.
Read Our Latest Research Report on AVBP
ArriVent BioPharma Stock Down 0.3 %
The business's 50 day moving average is $27.65 and its 200-day moving average is $25.72.
Hedge Funds Weigh In On ArriVent BioPharma
Several institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its stake in ArriVent BioPharma by 153.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 202,368 shares of the company's stock valued at $4,756,000 after buying an additional 122,641 shares during the period. Geode Capital Management LLC grew its stake in ArriVent BioPharma by 154.2% in the third quarter. Geode Capital Management LLC now owns 597,165 shares of the company's stock valued at $14,036,000 after purchasing an additional 362,221 shares in the last quarter. Barclays PLC boosted its holdings in shares of ArriVent BioPharma by 1,124.8% during the 3rd quarter. Barclays PLC now owns 41,522 shares of the company's stock worth $976,000 after buying an additional 38,132 shares during the period. State Street Corp boosted its stake in ArriVent BioPharma by 210.4% during the 3rd quarter. State Street Corp now owns 476,809 shares of the company's stock valued at $11,205,000 after purchasing an additional 323,186 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in ArriVent BioPharma by 32.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 21,965 shares of the company's stock valued at $516,000 after purchasing an additional 5,397 shares during the last quarter. 9.48% of the stock is owned by institutional investors.
ArriVent BioPharma Company Profile
(
Get Free Report)
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
Read More
Before you consider ArriVent BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.
While ArriVent BioPharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
